David Sherer

Dr. David Sherer is a retired physician and writer with over 40 years of experience in treating patients and their illnesses. He has a unique perspective on the American health care system and the factors contributing to the obesity epidemic. His areas of expertise include weight loss, nutrition, and lifestyle changes as opposed to relying solely on medication for treatment. His latest book is “Hunger Hijack, How Your Eating Habits are Changing Your Brain and Making You Sick” (Armin Lear Press, April 2024).

Biography:  https://www.baltimoresun.com/2024/04/14/want-to-slim-down-change-your-lifestyle-not-your-medication-guest-commentary/

79%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This author has a mixed reputation for journalistic standards. It is advisable to fact-check, scrutinize for bias, and check for conflicts of interest before relying on the author's reporting.

Bias

85%

Examples:

  • But do we really know the long-term ramifications of these agents? What does the science show?

Conflicts of Interest

100%

Examples:

No current examples available.

Contradictions

85%

Examples:

  • About 20% of Americans take five or more prescription medications, with about 85% taking at least one prescription medication.

Deceptions

45%

Examples:

  • In patients who desire to lose a small or moderate amount of weight, is it really worth the risks that have emerged in recent studies?
  • The coming shortage of doctors and nurses, along with spiraling health care spending, will force us to a reckoning that will shock many in the near future.
  • There have been reports, such as the one from October published in the Journal of the American Medical Association from The University of British Columbia. It linked GLP-1 agonists (Monjauro and Zepbound are in this class) to a nine times higher incidence of pancreatitis, an over four times the risk of bowel obstruction and a 3.67 times the risk of gastroparesis (stomach paralysis) when compared to using weight loss treatment bupropion and naltrexone.

Recent Articles

New Weight Loss Drugs: Impressive Results, Hefty Price Tags, and Accessibility Concerns

New Weight Loss Drugs: Impressive Results, Hefty Price Tags, and Accessibility Concerns

Broke On: Monday, 15 April 2024 Two new weight loss treatments, GLP-1 agonists like Wegovy and Ozempic, have generated buzz for their impressive results but high costs. With the US obesity market projected to surge with drug launches, affordability remains a concern. Despite these treatments' potential benefits, a healthy lifestyle is still the most effective approach to managing weight and overall health.